KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a drop of 6.1% from the January 15th total of 7,590,000 shares. Based on an average trading volume of 368,500 shares, the short-interest ratio is currently 19.3 days.

Analyst Ratings Changes

A number of equities research analysts recently commented on KALV shares. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $9.76 on Tuesday. The firm has a market cap of $482.34 million, a price-to-earnings ratio of -2.68 and a beta of 0.85. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.88. The stock has a 50-day simple moving average of $8.76 and a 200-day simple moving average of $10.45.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, equities research analysts predict that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 100,000 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $9.23 per share, for a total transaction of $923,000.00. Following the transaction, the insider now directly owns 5,217,285 shares in the company, valued at $48,155,540.55. This trade represents a 1.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the sale, the chief executive officer now owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased a total of 236,055 shares of company stock worth $2,162,146 over the last three months. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its stake in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,319 shares during the period. HighVista Strategies LLC lifted its stake in KalVista Pharmaceuticals by 4.5% in the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after buying an additional 1,432 shares during the period. Legal & General Group Plc lifted its stake in KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 1,494 shares during the period. JPMorgan Chase & Co. lifted its stake in KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after buying an additional 1,670 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).